Relationships
Relationship Details

Relationship Details

NLV-III → Financial → Pearl Therapeutics

Back to Relationships

Connected Entities

Entity A

NLV-III

Type: organization

Mentions: 66

Also known as: NLV-II, NLV-I

Entity B

Pearl Therapeutics

Type: organization

Mentions: 6

Evidence

Pearl Therapeutics (NLV-I, private, pulmonology, exited at 2.5x plus milestones)

Source Documents (1)

HOUSE_OVERSIGHT_024043.jpg

Investment Memorandum / Prospectus (Page 32) • 2.73 MB

View

This document is page 32 of a confidential investment memorandum (Control Number 257) produced for the House Oversight Committee. It outlines the investment strategy for 'NLV-III' (New Leaf Ventures III), focusing on biopharmaceutical companies with novel products or platforms. The text highlights past successes of the fund managers, listing exit multiples for companies such as Array BioPharma, Pearl Therapeutics, and Epizyme.

NLV-III's Other Relationships

Management contribution General Partner

Strength: 6/10 View

Management firm to fund New Leaf

Strength: 5/10 View

Financial Biopharma

Strength: 5/10 View

Management Fund Managers

Strength: 5/10 View

Management New Leaf

Strength: 5/10 View

Relationship Metadata

Type

Financial

Relationship Strength

5/10

Medium strength relationship

Source Documents

Extracted

2025-11-20 19:17

Entity Network Stats

NLV-III 9 relationships

Pearl Therapeutics 1 relationships

Mutual connections 0

Discussion 0

No comments yet

Be the first to share your thoughts on this epstein relationship